An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism

• Published in: Reproductive biology and endocrinology Vol. 15; no. 1; p. 17
• Main Authors: Nieschlag, Eberhard, Bouloux, Pierre-Marc G., Stegmann, Barbara J., Shankar, R. Ravi, Guan, Yanfen, Tzontcheva, Anjela, McCrary Sisk, Christine, Behre, Hermann M.
• Format: Journal Article
• Language: English
• Published: England BioMed Central 07.03.2017
• Subjects: Adult; Azoospermia - complications; Azoospermia - drug therapy; Chorionic Gonadotropin - therapeutic use; Drug Administration Schedule; Follicle Stimulating Hormone, Human - therapeutic use; Humans; Hypogonadism - complications; Hypogonadism - drug therapy; Male; Middle Aged; Organ Size - drug effects; Spermatogenesis - drug effects; Testis - drug effects; Testis - pathology; Treatment Outcome; Young Adult; Hypogonadotropic hypogonadism; Testis; Corifollitropin alfa; Gonadotropin deficiency; Male infertility

Hypogonadotropic hypogonadism (HH) in men results in insufficient testicular function and deficiencies in testosterone and spermatogenesis. Combinations of human chorionic gonadotropin (hCG) and recombinant follicle-stimulating hormone (recFSH) have been successful in the treatment of HH. Corifollit...